High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation for Myelofibrosis
This study is looking at whether giving ruxolitinib (a medication) and busulfan (a chemotherapy drug) before an allogeneic stem cell transplant (a procedure where you receive healthy blood-forming cells from a donor) can help people with myelofibrosis (a bone marrow disorder) who have an enlarged spleen (splenomegaly). The goal is to see if this approach can reduce spleen size and improve the success of the transplant. The study will enroll 30 participants aged 18 to 75 who have primary or secondary myelofibrosis and an enlarged spleen. Researchers will primarily be looking at the safety and side effects of this treatment plan. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 30 participants. It is not specified if it is randomized or single-arm.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Uday Popat, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0